1. Introduction {#sec1-ijerph-17-00416}
===============

Rheumatoid arthritis (RA) is a chronic autoimmune disease that mainly affects the joints causing inflammation, pain, and difficulty to use the joints. Although the exact cause is unknown, many genetic and environmental factors have been linked to the disease. Exposure to chemicals has previously been proposed as a possible, if not the main cause of the disease \[[@B1-ijerph-17-00416]\].

Several studies suggested that exposure of air pollution may increase the risk of RA \[[@B2-ijerph-17-00416],[@B3-ijerph-17-00416]\]. Furthermore, epidemiological evidence indicates a significant association between the risk of RA and exposure to environmental factors, such as cigarette smoke, dioxin, noise, and traffic-related air pollution \[[@B4-ijerph-17-00416],[@B5-ijerph-17-00416],[@B6-ijerph-17-00416]\].

Pollutants with the strongest evidence for public health concern include *particulate matter* (PM), *ozone* (O${}_{3}$), *nitrogen dioxide* (NO${}_{2}$), and *sulfur dioxide* (SO${}_{2}$) \[[@B7-ijerph-17-00416]\]. However, few studies have followed adequate methodologies correlating meteorological variables with RA. In this context, further investigation concerning the impact of air pollution on the risk of developing RA is still necessary.

With respect to RA, there is a need to investigate the impact of air pollution on RA through elaborate research. Air pollutants are part of the environmental components resulting from dust storms and fossil fuel combustion, which determine RA symptoms and worsen the overall disease. Additionally, gases such as SO${}_{2}$, NO${}_{2}$, *carbon monoxide* (CO), and O${}_{3}$ are the other main pollutants that cause RA \[[@B8-ijerph-17-00416]\]. More in general, extensive investigations have been performed by several researchers about the impact of ambient air pollution on human health \[[@B9-ijerph-17-00416],[@B10-ijerph-17-00416]\]. For instance, SO${}_{2}$ resulting from the combustion of fossil fuels with high sulfur content is considered one of the most common pollutants with the worst impact on air quality. The combustion of fossil fuels containing high sulfur content causes the release of sulfur dioxide into the atmosphere. Several researchers have adequately documented the harmful effects of long-term exposure to high levels of SO${}_{2}$ on overall health \[[@B11-ijerph-17-00416],[@B12-ijerph-17-00416]\]; therefore, increased emission of pollutants into the atmosphere may potentially result in several adverse health effects, including RA.

Many composite indices for RA progress measurement are actually available: for example, the Disease Activity Score (DAS) with 28 examined joints (DAS-28) is one common RA index that has been extensively employed to identify the disease progress level for RA patients \[[@B13-ijerph-17-00416],[@B14-ijerph-17-00416],[@B15-ijerph-17-00416]\]. The Disease Activity Score was developed to measure and assess RA disease activity in daily clinical practice, clinical trials, and long-term observational studies \[[@B16-ijerph-17-00416]\]. The second RA index is the Clinical Disease Activity index (CDAI) \[[@B17-ijerph-17-00416],[@B18-ijerph-17-00416]\], which is used to assess disease activity. The CDAI was developed to provide physicians and patients with simple and more understandable instruments.

In the present study, we aimed to investigate whether exposure to ambient air pollution (i.e., PM with aerodynamic diameter \< 10 µm (PM${}_{10}$), NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO) is associated with an increased risk of RA using the DAS-28 and CDAI indices.

2. Materials and Methods {#sec2-ijerph-17-00416}
========================

2.1. Patients Data Source (Kuwait Registry for Rheumatic Diseases---KRRD) {#sec2dot1-ijerph-17-00416}
-------------------------------------------------------------------------

The State of Kuwait is a small country with a total area equal to 17,818 km${}^{2}$ located on the far west side of the Asian continent. The total population of Kuwait is around 4.6 million, distributed into six main governorates \[[@B19-ijerph-17-00416]\]. All RA patients represented in this study were officially registered from the Kuwait Registry for Rheumatic Diseases (KRRD) from 2013 until the end of 2017. The KRRD is a national registry listing adult patients with rheumatic diseases. Patients who fulfilled the American College of Rheumatology (ACR) criteria for RA \[[@B20-ijerph-17-00416]\] registered from January 2013 to December 2017 were included in the study. The RA information data were collected from the rheumatology departments of four major government hospitals in Kuwait based on patient visits. The selected hospitals are mainly distributed in different governorates covering the ethnic diversity of the Kuwaiti population. The KRRD, from which this study originated, was approved by the Ethics Committees of the Faculty of Medicine at Kuwait University, and the Ministry of Health. Additionally, official consent was obtained from all represented patients enrolled in the registry \[[@B21-ijerph-17-00416]\].

2.2. Calculating RA Indices {#sec2dot2-ijerph-17-00416}
---------------------------

RA disease activity scores are measured using two different indices: DAS-28 and CDAI. The DAS-28 is the sum of four outcome parameters: TJC28, the number of tender joints (0--28); SJC28, the number of swollen joints (0--28); ESR, the erythrocyte sedimentation rate (in mm/h) (C-reactive protein (CRP) may be used as an alternative to ESR in the calculation); and GH, the patient global health assessment (from 0 = best to 100 = worst) (see Equation ([1](#FD1-ijerph-17-00416){ref-type="disp-formula"})).

The second index is The Clinical Disease Activity Index (CDAI). CDAI takes into account the following items: TJC28, the number of tender joints (0--28); SJC28, the number of swollen joints (0--28); PaGH, the patient global health assessment (from 0 = best to 10 = worst); and PrGH, the care provider global health assessment (from 0 = best to 10 = worst) (see Equation ([2](#FD2-ijerph-17-00416){ref-type="disp-formula"})). $${DAS} - 28 = 0.56 \times \sqrt{TJC28} + 0.28 \times \sqrt{SJC28} + 0.70 \times \ln\left( ESR Or CRP \right) + 0.014 \times GH$$ $${CDAI} = TJC28 + SJC28 + PaGH + \Pr GH$$

2.3. Ambient Air Pollutants Data (Environmental Public Authority of Kuwait---K-EPA) {#sec2dot3-ijerph-17-00416}
-----------------------------------------------------------------------------------

Pollutants data (PM${}_{10}$, NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO) were obtained from six fixed monitoring stations run by the Environmental Public Authority of Kuwait (K-EPA). The air pollutant measurement sampling was from 1 January 2013 to 31 December 2017 based on hourly observations.

The pollutant data were distributed throughout the residential areas where stations were measuring different parameters including PM${}_{10}$, NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO. The average concentration time of PM${}_{10}$, NO${}_{2}$, and SO${}_{2}$ was twenty-four hours, and eight-hour time-average concentrations of O${}_{3}$ and CO were collected for each measurement place, relying on 75% of the contributing values being present as the calculated averages.

According to Johnson et al. \[[@B22-ijerph-17-00416]\], the Air Quality Index (AQI) is defined as a measure of the condition of air relative to the requirements of one or more biotic species or to any human need \[[@B22-ijerph-17-00416],[@B23-ijerph-17-00416]\]. The AQI is divided into categories, in which they are numbered, and each slot is marked with a color code. This provides a scale from a healthy level of zero to a very hazardous level of above 300 as a health risk indicator associated with air quality.

In this study, the air quality was assessed using the AQI developed by Al-Shayji et al. \[[@B24-ijerph-17-00416]\] for the State of Kuwait, based on the guidelines proposed by the United States Environmental Protection Agency (USEPA) \[[@B25-ijerph-17-00416]\]. The AQI is an index for reporting the day-to-day air quality. It gives details about the cleanliness of ambient air. The following equation was used to convert from pollutant concentration to AQI:$$I_{p} = \frac{I_{high} - I_{low}}{C_{high} - C_{low}}\left( {C_{p} - C_{low}} \right) + I_{low},$$ where $I_{p}$ is the Air Quality Index for the given pollutant, $C_{p}$ is the pollutant concentration, $C_{low}$ is the concentration breakpoint that is $\leq C_{p}$, $C_{high}$ is the concentration breakpoint that is $\geq C_{p}$, $I_{low}$ is the index breakpoint corresponding to $C_{low}$, and $I_{high}$ is the index breakpoint corresponding to $C_{high}$ \[[@B26-ijerph-17-00416]\] (see [Table 1](#ijerph-17-00416-t001){ref-type="table"}).

2.4. Air Pollution Data Processing and Treatment {#sec2dot4-ijerph-17-00416}
------------------------------------------------

AQI data were examined by checking the normality assumption and detecting for any possible outliers before any statistical analysis or testing between the variables were done. About 5.8%, 1.6%, 48.4%, 5.3%, and 6.5% of data for PM${}_{10}$, NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO were missing, respectively. Multiple imputations were performed to improve the accuracy of AQI prediction, where a final estimate was composed of the outputs of several multivariate fill-in methods \[[@B27-ijerph-17-00416],[@B28-ijerph-17-00416]\].

The imputation process was determined by considering log transformation for better prediction to estimate and filling the missing data for each pollutant. Finally, AQI with RA information were matched with patients' hospital location and date of patient visit. All AQI data for every pollutant were aggregated from hourly to daily observation.

2.5. Matching Procedure between Patients and AQI {#sec2dot5-ijerph-17-00416}
------------------------------------------------

All data management and combination was conducted using R Studio Version 1.1.463 running R 3.5.1 GUI 1.70 \[[@B29-ijerph-17-00416]\] software. Various R packages were used to clean, match, and combine the two datasets, including $plyr$ \[[@B30-ijerph-17-00416]\], $dplyr$ \[[@B31-ijerph-17-00416]\], $tidyr$ \[[@B32-ijerph-17-00416]\], and $stringr$ \[[@B33-ijerph-17-00416]\].

The matching procedure was done using a developed R code to match between RA patient information and AQI monitoring station using date and governorate variables for both KRRD and K-EPA. As mentioned above, air pollution information was taken from six different stations distributed into all six governorates in the state of Kuwait. The matching procedure was conditioned on the date of patient visit with the date of the daily average AQI using a developed R code grouped by governorate physical address (e.g., if a patient lived in the Ahmadi governorate, the AQI information that came from the Ahmadi monitoring station was added to their visit information after matching the same date; see [Figure 1](#ijerph-17-00416-f001){ref-type="fig"}).

2.6. Statistical Analysis {#sec2dot6-ijerph-17-00416}
-------------------------

In the current study, means, standard deviations (SDs), and percentages were used to summarize and compare RA characteristics between the governorate levels. To estimate the association between the pollutants and RA indices, hierarchal linear model (HLM) analysis was performed using a regression approach. Pearson correlation test was performed to highlight the significant associations between AQI for NO${}_{2}$, CO, PM${}_{10}$, SO${}_{2}$, and O${}_{3}$ and with the RA indices (DAS-28 and CDAI). Regression analyses were performed separately for DAS-28 and CDAI as response variables. Four regression models were estimated to highlight the most significant variables associated with the response variables (DAS-28 or CDAI). Because the variables belong to two different databases, we started with the first regression (M1) that measured the association between patients demographics (e.g., gender, RA disease duration, nationality, governorate, and comorbidity) with the response variables (DAS-28 or CDAI), and then we estimated the second regression model (M2) that measured the association between rheumatoid factors after adjusting for gender, RA disease duration, nationality, governorate, and comorbidity with the response variables (DAS-28 or CDAI). Models 1 and 2 were estimated from KRRD database. Then, we estimated Models 3 and 4 to highlight if there is any association between air pollution with disease activity indices (DAS-28 or CDAI) after merging the EPA with KRRD databases. Model 3 (M3) measured the direct effect from air pollutants to disease activity indices (DAS-28 or CDAI), whereas Model 4 (M4) measured the association between air pollutants to disease activity indices after adjusting for the rheumatoid factors mentioned in Model 2 (M2) (e.g., comorbidity, treatment class, swollen, tender, etc.). For better data fit, model comparison techniques using deviance scores were implemented to confirm the best choice of model \[[@B34-ijerph-17-00416],[@B35-ijerph-17-00416]\]. All statistical procedures were performed using Stata 15.1 SE version software (StataCorp, College Station, TX, USA).

Model 1 (M1) was made to explain the influence of demographic variables (Disease Duration, Gender, Governorate, Nationality, Comorbidity, and Treatment Class) on the response variables (DAS-28 and CDAI). Model 2 (M2) was made to determine the effect of RA factors (Swollen, Tender, RF (rheumatoid factor), ACPA, Patient Global Assessment, and Physician Global Assessment) plus demographics on the response variables. Model 3 (M3) was made to estimate the relationship between the increase of NO${}_{2}$, CO, PM${}_{10}$, SO${}_{2}$, and O${}_{3}$ concentrations and the response variables (DAS-28 and CDAI). Model 4 (M4) was made to explain the effect of AQI in terms of NO${}_{2}$, CO, PM${}_{10}$, SO${}_{2}$, and O${}_{3}$ with RA factors (Swollen, RF, ACPA (anti-cyclic citrullinated peptide), ESR, and CRP) to indicate RA disease activity.

3. Results {#sec3-ijerph-17-00416}
==========

The data of RA patients visits were obtained from KRRD, and the air pollution data were obtained from K-EPA. The analysis was performed during the period from 2013 to the end of 2017. There were 1651 RA patients with 9875 follow-up visits and 13,152 daily air pollution records. Because of the matching process to combine the data from the air pollution dataset with the RA patient visits from the KRRD dataset, the final dataset had to meet the matching conditions (matching based on date and governorate) with a total of 9875 records.

[Table 2](#ijerph-17-00416-t002){ref-type="table"} shows some information about RA patient characteristics group by governorate location in the state of Kuwait. From the results, most patients were from Fawaniya governorate (n = 4378 visits; 44.3%). Most of the patients belonged to the local country with Kuwaiti nationality (n = 5783 visits; 58.6%). Females accounted for the majority of total visits (n = 6008; 60.8%). The average RA disease duration for all patients was 9.82 years with a SD of 6.48 years.

Most of the patients were positive for rheumatoid factor (RF; n = 6881; 74.6%) and positive for anti-cyclic citrullinated peptide (ACPA; n = 4934; 60.5%). The majority of RA patients presented co-morbidities (e.g., hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, coronary artery disease, cancer, or any other illness; n = 5393; 54.6%). From the results, most of the consumed drugs were biologics (n = 5214; 52.8%).

In [Table 2](#ijerph-17-00416-t002){ref-type="table"}, we can see that most RA patients visited Al-Amiri hospital, with total visits n = 5051 (51.1%). Al-Amiri hospital is the only hospital in the Kuwait City governorate. The second-most patients were from Farwaniya hospital, with total visits numbering n = 3981 (40.3%). Farwaniya Hospital is the only public general hospital in Al Farwaniyah governorate. In Kuwait, there are six governorates, and each governorate has only one hospital.

With regard to disease activity, results in [Table 2](#ijerph-17-00416-t002){ref-type="table"} present the clinical features of all RA patient visits. The average DAS-28 score was 2.67 with SD 1.26, and the average score of CDAI was 6.24 with a SD of 9.96, both indicating a low disease activity. The average and SD scores for ESR and CRP were $\overline{x} = 27.19$ mm/h and SD $= 21.79$ and $\overline{x} = 6.32$ mg/L and SD $= 4.85$, respectively, which were both within the normal ranges according to our laboratory. Moreover, the average and SD for swollen and tender joints for all RA patient visits were $\overline{x} = 0.69$ and SD $= 2.26$ and $\overline{x} = 2.87$ and SD $= 5.60$, respectively.

[Table 3](#ijerph-17-00416-t003){ref-type="table"} shows the average air pollutant concentrations using AQI scores. The mean and SD AQIs for PM${}_{10}$, CO, NO${}_{2}$, O${}_{3}$, and SO${}_{2}$ were $167.62 \pm 214.27$, $1.28 \pm 0.61$, $47.98 \pm 26.64$, $17.76 \pm 8.94$, and $15.87 \pm 17.66$, respectively. The mean exposure levels for PM${}_{10}$, CO, NO${}_{2}$, O${}_{3}$, and SO${}_{2}$ in Group 2 were $158.51 \pm 68.02$, $1.31 \pm 0.44$, $42.74 \pm 18.83$, $18.17 \pm 7.56$, and $\left. 13.94 \pm 12.04 \right)$, respectively. [Figure 2](#ijerph-17-00416-f002){ref-type="fig"} shows the monthly AQI average time series for PM${}_{10}$, CO, NO${}_{2}$, O${}_{3}$, and SO${}_{2}$.

Moreover, all pollutants distribution are positively skewed (i.e., the means are higher than the medians for all pollutants). However, log transformation was employed to all pollutants in the regression model for better and quality parameter estimation. Logarithmic transformation pulls extreme values in the pollutants into the normal distribution. In the regression modeling, the logarithmic transformation is not considered, as linear explanation of the regression model is made easier to transform all other variables in the model with the same logarithmic transformation. However, this is not necessary as long as all other variables achieved the normality assumption.

Correlation analysis using Pearson correlation test was conducted to highlight the significant relationship between the pollutants (PM${}_{10}$, NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO). [Table 4](#ijerph-17-00416-t004){ref-type="table"} shows significant positive correlations between NO${}_{2}$ and CO ($r_{p}$ = 0.22), NO${}_{2}$ and SO${}_{2}$ ($r_{p}$ = 0.51), and O${}_{3}$ and PM${}_{10}$ ($r_{p}$ = 0.08). Significant negative correlations were discovered between O${}_{3}$ and NO${}_{2}$ ($r_{p}$ = −0.12), PM${}_{10}$ and NO${}_{2}$ ($r_{p}$ = −0.12), PM${}_{10}$ and SO${}_{2}$ ($r_{p}$ = −0.03), and PM${}_{10}$ and CO ($r_{p}$ = −0.05).

[Table 4](#ijerph-17-00416-t004){ref-type="table"} presents the Pearson correlation coefficients between different air pollutants and RA variables. For the score of RA disease activity using the DAS-28 index, the correlation results showed a positive significant correlation with exposure of SO${}_{2}$ using AQI ($r_{p} = 0.07$), and the same results were returned with the with the exposure to NO${}_{2}$ using AQI ($r_{p} = 0.07$). As for particular pollutants, only Hart et al. \[[@B36-ijerph-17-00416]\] provided evidence of elevated risks for NO${}_{2}$ and SO${}_{2}$, especially in terms of seronegative RA. Other pollutants (PM${}_{10}$, CO, and O${}_{3}$) did not show any significant correlation. For the CDAI, the correlation results showed a positive significant correlation with exposure to SO${}_{2}$ using AQI ($r_{p} = 0.10$), and the same results were returned with the exposure to NO${}_{2}$ ($r_{p} = 0.11$). Other pollutants (PM${}_{10}$, CO, and O${}_{3}$) did not show any significant correlation with CDAI. For PM${}_{10}$, Hart et al. \[[@B36-ijerph-17-00416]\] reported an elevated odds ratio (OR), which failed to reach statistical significance. The effects of both $PM_{2.5}$ and PM${}_{10}$ were non-significant across the analyses, but were consistently more pronounced for seronegative RA.

[Table 5](#ijerph-17-00416-t005){ref-type="table"} and [Table 6](#ijerph-17-00416-t006){ref-type="table"} present the hierarchal linear model (HLM) analysis using multiple linear regression. The first model (M1) demonstrates the effect of patient demographics on RA disease activity, where DAS-28 and CDAI were the response variables (see [Table 5](#ijerph-17-00416-t005){ref-type="table"} and [Table 6](#ijerph-17-00416-t006){ref-type="table"}). For both DAS-28 and CDAI, the demographics explained the disease activity scores ($R_{DAS - 28}^{2} = 0.034$ and $R_{CDAI}^{2} = 0.030$). RA Disease Duration was not significant for DAS-28, but it had a significant association with CDAI (see [Table 6](#ijerph-17-00416-t006){ref-type="table"} (M1)). Model 2 (M2) shows that RA factors (Swollen, Tender, RF, ACPA, Patient Global Assessment, Physician Global Assessment, ESR, and CRP) plus demographics affected DAS-28 ($R^{2} = 0.865$) and CDAI ($R^{2} = 0.924$). In the CDAI model (M2), Gender and RA Disease Duration were not significant in explaining the CDAI. Model 3 (M3) demonstrated and highlighted the effects of gaseous pollutants (PM${}_{10}$, NO${}_{2}$, SO${}_{2}$, O${}_{3}$, and CO) using AQI on RA disease activity; only SO${}_{2}$ and NO${}_{2}$ were significant risk factors for RA patients using the information of DAS-28 ($R^{2} = 0.007$) and CDAI ($R^{2} = 0.015$). The final model demonstrated the effect of gaseous air pollutants with RA factors (Swollen, RF, ACPA, ESR, and CRP) on RA disease activity. The AQI of NO${}_{2}$ and SO${}_{2}$ still showed positive associations with disease activity performance of RA. The positive effects of NO${}_{2}$ in Model 4 (M4) were $\beta = 0.003$ (95% CI: 0.002--0.005) and $\beta = 0.048$ (95% CI: 0.030--0.066) for DAS-28 and CDAI, respectively (e.g., for a 1 $\mu g/m^{3}$ increase in daily concentration of NO${}_{2}$, DAS-28 index will increase by 0.002 (95%CI:0.002--0.005) and CDAI index will increase by 0.048 (95% CI: 0.030--0.066)), whereas, for SO${}_{2}$, the results showed a positive significant effect with $\beta = 0.003$ (95% CI: 0.0004--0.005) and $\beta = 0.044$ (95% CI: 0.018--0.070) for DAS-28 and CDAI, respectively (e.g., for 1 $\mathsf{\mu}g/m^{3}$ increase in daily concentration of SO${}_{2}$, DAS-28 index will increase by 0.003 (95%CI: 0.0004--0.005) and CDAI index will increase by 0.044 (95% CI: 0.018--0.070)).

4. Discussion {#sec4-ijerph-17-00416}
=============

Air pollution is a major concern for human health, since it is known to trigger and/or induce several pathologies and subsequently to increase morbidity and mortality rates, particularly in the Middle Eastern countries such as Kuwait. Therefore, air pollution control is a crucial element that should be prioritized by governments. According to the World Health Organization (WHO), six major air pollutants including NO${}_{2}$, CO, PM${}_{10}$, SO${}_{2}$, O${}_{3}$, and lead ($Pb$) were identified to be primary and secondary pollutants with health risks. Many studies have found connections between particulates in the air and rates of hospitalization, chronic obstructive pulmonary disease, and restricted activity due to illness \[[@B7-ijerph-17-00416]\].

RA is considered as the most common chronic systemic auto-immune disease affecting joints, musculoskeletal apparatus, and fibrous tissues \[[@B37-ijerph-17-00416]\], whose incidence is expected to follow a positive trend during the following years \[[@B38-ijerph-17-00416]\].

Our findings show a significant relationship between the concentration of certain air pollutants and RA disease activity: particularly, our results show that increased SO${}_{2}$ and NO${}_{2}$ concentrations may increase the risk of developing RA disease activity using the index DAS-28 or CDAI. These results agree with those reported in other studies \[[@B36-ijerph-17-00416],[@B39-ijerph-17-00416]\].

Concerning PM${}_{10}$, O${}_{3}$, and CO, our results do not show any effect being significant enough for considering them as risk factors of RA disease activity in terms of DAS-28 index; however, O${}_{3}$ was found to be a risk factor together with SO${}_{2}$ and NO${}_{2}$ in terms of predicting RA disease activity using CDAI. A study from Korea reported an increased risk for developing RA in adults exposed to increased O${}_{3}$ and CO concentrations \[[@B40-ijerph-17-00416]\].

For better understanding, the major sources of air pollutants in Kuwait are oil refineries, traffic, and power plants (mostly using fossil fuels), which are thought to be the main sources of SO${}_{2}$ and NO${}_{2}$ in Kuwait City \[[@B41-ijerph-17-00416]\]. Indeed, urban pollution results from various sources, including industrial activities and traffic within cities: more specifically, the most prevalent pollutants generated from road transport are NO${}_{2}$, CO, SO${}_{2}$, volatile organic compounds (VOCs), and $PM$ \[[@B42-ijerph-17-00416]\].

Particularly, Kuwait---with a population of over four million people and a fleet of more than two million vehicles, both growing rapidly---is experiencing increases in traffic volumes, trip frequency, and trip length \[[@B43-ijerph-17-00416]\]; therefore, the poor air quality outdoors is becoming a major concern, especially for people living in Kuwait City. Kuwait is a relatively small country, with a high quantity of fixed and mobile sources of different pollutants affecting air quality, especially with a high level of road traffic. As a major oil supplier in the region, fossil fuel combustion products emitted by power stations and water distillation plants are liable for the elevated atmospheric SO${}_{2}$ concentrations, whereas VOCs and NO${}_{2}$ concentrations are mainly increased by automobiles \[[@B41-ijerph-17-00416]\].

In the present study, the relation between air pollutants and RA disease activity was measured using several regression models, to ensure that this association was still present even after the addition of RA factors that were highly significant for DAS-28 and CDAI. From Model 1 for both DAS-28 and CDAI, demographics controlled the disease activity level; these results comply with patient-reported outcomes used by the National Databank for Rheumatic Diseases (NDB) \[[@B44-ijerph-17-00416],[@B45-ijerph-17-00416]\].

The results of Model 1 did not show any significant evidence concerning the effect of disease duration on the disease activity level as measured by the DAS-28; this also agrees with another study \[[@B46-ijerph-17-00416]\]. Nonetheless, the results of Models 3 and 4 confirmed the existence of a significant association between exposure to SO${}_{2}$ and NO${}_{2}$ and increase of RA disease activity: more specifically, in Model 3, where the effect of air pollutants was presented without adding RA variables, SO${}_{2}$ and NO${}_{2}$ showed significant relationships with RA's disease activity; in Model 4, where other RA factors were included, SO${}_{2}$ and NO${}_{2}$ remained risk factors for RA disease activity level.

The Swedish Epidemiological Investigation examined the impact of prolonged exposure to air pollution on the probability of having RA: from this research, there was no evidence of a higher risk of RA resulting from exposure to PM; additionally, the overall risk of RA mildly increased due to atmospheric pollutants. This research confirmed the presence of a higher risk of RA following increases in NO${}_{2}$ and SO${}_{2}$ concentrations in ambient air \[[@B36-ijerph-17-00416]\].

Among these various fields of research, a study using distance-to-road as a proxy component for exposure to traffic-associated pollution reported a substantial increase of RA risk in those residing within shorter distances from the road \[[@B4-ijerph-17-00416]\]. Moreover, a Canadian nested case-control study reported an augmented risk of developing RA following exposure to O${}_{3}$ \[[@B5-ijerph-17-00416]\]. In another case-control study, a significant increase in the risk of RA was reported in line with increasing concentrations of NO${}_{2}$ and SO${}_{2}$ \[[@B36-ijerph-17-00416]\]. Furthermore, other studies suggested an increased risk of RA in subjects who were exposed to NO${}_{2}$, particularly in women \[[@B1-ijerph-17-00416]\], as well as positive associations between O${}_{3}$, CO, and NO${}_{2}$ and RA incidence \[[@B47-ijerph-17-00416]\].

This study has some strengths such as combining patients records with air pollution concentration to initiate a complete dataset that could be used for future academic studies. In addition, dealing with missing values using MICE algorithm increased the accuracy of the estimated regression coefficients. This study used KRRD database that includes data on RA patients in Kuwait with all previous records. One of the Limitations in the study is related to the records of the follow-up visits. As the data were extracted from a registry, the number of hospital visits is not equal for all patients. It ranges from 1 to 49 visits. Because of this limitation, time series analysis during patients visits could not be performed to estimate lag effect between air pollution and RA disease activity. Single lag day effect or moving average of several previous days lag effect could not be investigated in this study because of the data layout and the study duration is very short (from 2013 to 2017). However, it could be developed by improving time series features in the future.

5. Conclusions {#sec5-ijerph-17-00416}
==============

Air pollution was significantly associated with disease activity scores in RA patients. NO${}_{2}$ and SO${}_{2}$ were found to be significant risk factors for RA activity, with 7% positive correlation with disease activity indices DAS-28 and CDAI. Future research could also be based on time-series analysis by employing univariate or multivariate time series analysis. It is also recommended that researchers classify the data on air pollution and disease activity score using a cluster technique and perform an adequate cluster analysis on the data.
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###### 

Kuwait Air Quality Index. PM${}_{10}$: particulate matter with aerodynamic diameter ≤10 $\mathsf{\mu}$m.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Categories       AQI,\       O$\mathbf{{}_{3}}$ (ppm),\   PM$\mathbf{{}_{10}}$ (µg/m$\mathbf{{}^{3}}$),\   CO (ppm),\   SO$\mathbf{{}_{2}}$ (ppm),\   NO$\mathbf{{}_{2}}$ (ppm),\
                   Sub-Index   8-h                          24-h                                             24-h         24-h                          24-h
  ---------------- ----------- ---------------------------- ------------------------------------------------ ------------ ----------------------------- -----------------------------
  Good             0--50       0.0--0.03                    0.0--90                                          0.0--4.0     0.0--0.03                     0.0--0.03

  Moderate         51--100     0.031--0.06                  90.1--350.0                                      4.1--8.0     0.031--0.06                   0.04--0.05

  Unhealthy (1)    101--150    0.061--0.092                 350.1--431.1                                     8.1--11.7    0.061--0.182                  0.06--0.30

  Unhealthy (2)    151--200    0.093--0.124                 431.4--512.5                                     11.8--15.4   0.183--0.304                  0.31--0.55

  Very Unhealthy   201--300    0.125--0.374                 512.6--675.0                                     15.5--30.4   0.305--0.604                  0.56--1.04

  Hazardous        301--500    0.375--0.504                 675.1--1000                                      30.5--50.4   0.605--1.004                  1.05--2.04
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

RA patient visit demographic and clinical features groups by governorate---2012 to 2017.

                              \[ALL\]         Ahmadi          Farwaniya       Hawally         Jahra           Kuwait City     Mubarak
  --------------------------- --------------- --------------- --------------- --------------- --------------- --------------- ----------------------
                              **n = 9875**    **n = 356**     **n = 4378**    **n = 1272**    **n = 226**     **n = 3007**    **Alkabeer n = 636**
  Gender:                                                                                                                     
    male                      3867 (39.2%)    73 (20.5%)      2656 (60.7%)    285 (22.4%)     82 (36.3%)      653 (21.7%)     118 (18.6%)
    female                    6008 (60.8%)    283 (79.5%)     1722 (39.3%)    987 (77.6%)     144 (63.7%)     2354 (78.3%)    518 (81.4%)
  Nationality:                                                                                                                
    Kuwaitis                  5783 (58.6%)    328 (92.1%)     1499 (34.2%)    773 (60.8%)     145 (64.2%)     2462 (81.9%)    576 (90.6%)
    non-Kuwaitis              4092 (41.4%)    28 (7.87%)      2879 (65.8%)    499 (39.2%)     81 (35.8%)      545 (18.1%)     60 (9.43%)
  Visited Hospital:                                                                                                           
    Amiri                     5051 (51.1%)    294 (82.6%)     364 (8.31%)     774 (60.8%)     120 (53.1%)     2955 (98.3%)    544 (85.5%)
    Farwaniya                 3981 (40.3%)    0 (0.00%)       3976 (90.8%)    5 (0.39%)       0 (0.00%)       0 (0.00%)       0 (0.00%)
    Jahra                     111 (1.12%)     0 (0.00%)       2 (0.05%)       3 (0.24%)       106 (46.9%)     0 (0.00%)       0 (0.00%)
    Mubarak                   732 (7.41%)     62 (17.4%)      36 (0.82%)      490 (38.5%)     0 (0.00%)       52 (1.73%)      92 (14.5%)
  Disease Duration ${}^{3}$   9.82 (6.48)     13.3 (9.11)     9.39 (5.79)     10.4 (7.03)     10.2 (6.45)     9.42 (5.78)     11.4 (9.60)
  Comorbidity ${}^{2}$:                                                                                                       
    Yes                       5393 (54.6%)    226 (63.5%)     1658 (37.9%)    802 (63.1%)     123 (54.4%)     2157 (71.7%)    427 (67.1%)
    No                        4482 (45.4%)    130 (36.5%)     2720 (62.1%)    470 (36.9%)     103 (45.6%)     850 (28.3%)     209 (32.9%)
  Treatment Class:                                                                                                            
    Biologics                 5214 (52.8%)    327 (91.9%)     1342 (30.7%)    762 (59.9%)     131 (58.0%)     2124 (70.6%)    528 (83.0%)
    cDMARDs ${}^{4}$          4661 (47.2%)    29 (8.15%)      3036 (69.3%)    510 (40.1%)     95 (42.0%)      883 (29.4%)     108 (17.0%)
  RF ${}^{1}$:                                                                                                                
    Positive                  6881 (74.6%)    235 (72.8%)     3148 (76.3%)    817 (71.0%)     177 (93.2%)     2042 (72.0%)    462 (76.5%)
    Negative                  2348 (25.4%)    88 (27.2%)      976 (23.7%)     334 (29.0%)     13 (6.84%)      795 (28.0%)     142 (23.5%)
  ACPA:                                                                                                                       
    Positive                  4934 (60.5%)    102 (33.6%)     2665 (70.3%)    593 (63.1%)     73 (61.3%)      1205 (48.1%)    296 (60.0%)
    Negative                  3216 (39.5%)    202 (66.4%)     1125 (29.7%)    347 (36.9%)     46 (38.7%)      1299 (51.9%)    197 (40.0%)
  Patient GA                  1.64 (2.36)     1.54 (2.34)     1.02 (1.85)     2.60 (2.69)     2.09 (2.52)     1.95 (2.56)     2.39 (2.69)
  Physician GA                1.05 (1.77)     1.06 (1.82)     0.72 (1.50)     1.63 (2.02)     1.58 (2.21)     1.13 (1.78)     1.64 (2.18)
  DAS-28                      2.67 (1.26)     1.85 (1.35)     2.70 (1.21)     2.77 (1.29)     3.04 (1.39)     2.61 (1.22)     2.79 (1.44)
  CDAI                        6.24 (9.96)     4.64 (8.89)     4.83 (8.56)     8.31(10.72)     9.45 (14.25)    6.78 (10.49)    9.00 (11.53)
  ESR                         27.19 (21.79)   15.12 (16.82)   30.24 (23.10)   26.77 (20.30)   30.06 (19.33)   23.97 (19.54)   27.80 (24.04)
  CRP                         6.32 (4.85)     4.32 (3.91)     7.29 (4.89)     4.53 (4.53)     6.36 (4.42)     6.08 (4.68)     5.38 (4.87)
  Swollen Joints              0.69 (2.26)     0.34 (1.57)     1.08 (2.60)     0.53 (1.97)     0.95 (3.63)     0.26 (1.67)     0.57 (1.99)
  Tender Joints               2.87 (5.60)     1.72 (4.32)     2.02 (4.18)     3.55 (6.21)     4.82 (8.39)     3.46 (6.36)     4.54 (7.13)

${}^{1}$ RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibody. ${}^{2}$ Comorbidity (e.g., hypertension, hyperlipidemia, diabetes mellitus, etc.); ${}^{3}$ Disease Duration, RA disease duration by years. ${}^{4}$ DMARDs, conventional disease modifying anti-rheumatic drugs. GA, global assessment.
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###### 

Distribution of Kuwait ambient air pollution exposure using AQI during 2012--2017.

  Air Pollutant          Ahmadi (n = 356)   Farwaniya (n = 4378)   Hawally (n = 1272)   Jahra (n = 226)   Kuwait City (n = 3007)   Mubarak Alkabeer (n = 636)   ALL (n = 9875)
  ---------------------- ------------------ ---------------------- -------------------- ----------------- ------------------------ ---------------------------- -----------------
  **PM** ${}_{10}$                                                                                                                                              
    min                  17.108             20.346                 21.948               18.837            12.138                   5.421                        5.421
    25th ${}^{1}$        75.839             76.312                 80.692               67.417            71.114                   74.886                       74.965
    median               112.623            120.779                113.586              92.788            116.081                  109.917                      113.586
    75th ${}^{2}$        180.403            186.145                180.581              151.762           193.121                  184.282                      186.568
    max                  549.419            511.826                588.494              545.789           577.706                  585.077                      588.494
    mean (SD ${}^{3}$)   142.36 ± 99.58     146.47 ± 94.20         145.69 ± 99.23       123.64 ± 95.00    146.81 ± 102.42          142.40 ± 102.79              144.87 ± 100.64
  **CO**                                                                                                                                                        
    min                  0.240              0.207                  0.087                0.042             0.087                    0.292                        0.042
    25th                 0.938              0.945                  0.984                0.854             1.006                    0.978                        0.975
    median               1.367              1.338                  1.337                1.151             1.369                    1.380                        1.346
    75th                 1.679              1.603                  1.672                1.455             1.679                    1.728                        1.672
    max                  4.894              4.701                  4.471                5.122             8.143                    5.287                        8.143
    mean (SD)            1.37 ± 0.62        1.33 ± 0.57            1.40 ± 0.66          1.14 ± 0.64       1.40 ± 0.66              1.46 ± 0.70                  1.39 ± 0.66
  **NO** ${}_{2}$                                                                                                                                               
    min                  9.080              9.080                  5.346                8.229             5.346                    5.346                        5.346
    25th                 25.768             28.200                 27.208               29.127            27.319                   32.037                       27.391
    median               35.762             36.537                 35.810               52.420            36.795                   44.744                       37.355
    75th                 54.218             53.150                 51.409               67.866            52.054                   68.210                       54.552
    max                  137.960            135.878                134.123              107.279           208.670                  207.557                      208.670
    mean (SD)            42.85 ± 24.13      42.01 ± 20.70          41.29 ± 20.60        50.92 ± 25.54     43.00 ± 22.76            52.09 ± 27.91                43.74 ± 23.13
  **O** ${}_{3}$                                                                                                                                                
    min                  4.051              4.051                  4.051                5.887             3.476                    4.877                        3.476
    25th                 10.965             11.030                 10.851               12.457            10.581                   11.328                       10.851
    median               15.215             15.372                 15.104               18.192            14.709                   14.164                       14.985
    75th                 20.874             22.240                 20.451               25.172            20.451                   19.507                       20.759
    max                  54.262             69.682                 80.656               37.539            88.623                   57.330                       88.623
    mean (SD)            17.04 ± 8.75       18.53 ± 11.27          17.58 ± 10.52        18.71 ± 7.24      16.85 ± 10.08            16.26 ± 7.51                 17.19 ± 9.90
  **SO** ${}_{2}$                                                                                                                                               
    min                  0.003              1.000                  1.000                0.665             0.003                    1.000                        0.003
    25th                 4.208              5.293                  4.875                5.435             4.490                    7.333                        4.875
    median               8.333              8.000                  8.594                13.792            7.993                    14.083                       8.727
    75th                 14.146             17.292                 17.169               24.583            16.746                   22.946                       17.504
    max                  121.833            121.833                121.833              76.875            111.917                  127.875                      127.875
    mean (SD)            13.15 ± 15.46      13.26 ± 14.22          14.18 ± 16.10        17.90 ± 16.52     13.39 ± 14.60            18.62 ± 17.07                14.26 ± 15.42

^1^ 25th, lower quartile (25th percentile). ^2^ 75th, upper quartile (75th percentile). ^3^ SD: standard deviation.
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###### 

Correlation analysis between rheumatoid arthritis disease factors and AQI for SO${}_{2}$, NO${}_{2}$, CO, O${}_{3}$, and PM${}_{10}$.

                DAS-28          CDAI            NO$\mathbf{{}_{2}}$   O$\mathbf{{}_{3}}$   SO$\mathbf{{}_{2}}$   CO           PM$\mathbf{{}_{10}}$   Swollen         Tender          ESR
  ------------- --------------- --------------- --------------------- -------------------- --------------------- ------------ ---------------------- --------------- --------------- ---------------
  DAS-28                                                                                                                                                                             
  CDAI          0.77 \*\*\*\*                                                                                                                                                        
  NO${}_{2}$    0.07 \*\*\*\*   0.11 \*\*\*\*                                                                                                                                        
  O${}_{3}$     0.00            0.00            −0.12 \*\*\*\*                                                                                                                       
  SO${}_{2}$    0.07 \*\*\*\*   0.10 \*\*\*\*   0.51 \*\*\*\*         −0.09 \*\*\*\*                                                                                                 
  CO            −0.01           0.02            0.22 \*\*\*\*         0.02                 0.07 \*\*\*\*                                                                             
  PM${}_{10}$   0.00            −0.02           −0.12 \*\*\*\*        0.08 \*\*\*\*        −0.03 \*              −0.05 \*\*                                                          
  Swollen       0.50 \*\*\*\*   0.60 \*\*\*\*   0.01                  0.01                 0.01                  0.00         −0.02                                                  
  Tender        0.72 \*\*\*\*   0.93 \*\*\*\*   0.13 \*\*\*\*         0.01                 0.11 \*\*\*\*         0.03         −0.01                  0.42 \*\*\*\*                   
  ESR           0.65 \*\*\*\*   0.20 \*\*\*\*   0.00                  −0.02                0.04 \*               −0.04 \*     0.02                   0.16 \*\*\*\*   0.17 \*\*\*\*   
  CRP           0.28 \*\*\*\*   0.02 \*         0.01                  0.02                 0.01                  −0.01        −0.01                  0.11 \*\*\*\*   0.02 \*         0.37 \*\*\*\*

Note: \* *p* \< 0.1; \*\* *p* \< 0.05; \*\*\* *p* \< 0.01; \*\*\*\* *p* \< 0.001.
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###### 

Coefficients estimated by hierarchal linear model (HLM) for DAS-28 (standard error in parentheses).

                                   Dependent Variable                                         
  -------------------------------- -------------------- ------------------ ------------------ -------------------
  Gender (male)                    −0.213 \*\*\*        −0.040 \*\*\*                         
                                   (−0.268, −0.157)     (−0.064, −0.017)                      
  RA Disease Duration              −0.002               −0.004 \*\*\*                         
                                   (−0.006, 0.002)      (−0.006, −0.003)                      
  Nationality (non-Kuwaitis)       0.272 \*\*\*         0.022                                 
                                   (0.214, 0.331)       (−0.007, 0.051)                       
  Governorate (Farwaniya)          0.807 \*\*\*         0.299 \*\*\*                          
                                   (0.666, 0.947)       (0.239, 0.358)                        
  Governorate (Hawally)            0.852 \*\*\*         0.277 \*\*\*                          
                                   (0.704, 1.000)       (0.214, 0.341)                        
  Governorate (Jahra)              1.143 \*\*\*         0.254 \*\*\*                          
                                   (0.933, 1.352)       (0.150, 0.359)                        
  Governorate (Kuwait City)        0.744 \*\*\*         0.290 \*\*\*                          
                                   (0.606, 0.882)       (0.232, 0.348)                        
  Governorate (Mubarak Alkabeer)   0.955 \*\*\*         0.175 \*\*\*                          
                                   (0.793, 1.117)       (0.106, 0.244)                        
  Comorbidity (Yes)                0.060 \*\*           −0.051 \*\*\*                         
                                   (0.007, 0.114)       (−0.074, −0.029)                      
  Treatment Class (cDMARDs)                             0.064 \*\*\*                          
                                                        (0.036, 0.092)                        
  Swollen                                               0.090 \*\*\*                          0.226 \*\*\*
                                                        (0.085, 0.095)                        (0.208, 0.244)
  Tender                                                0.099 \*\*\*                          
                                                        (0.096, 0.101)                        
  RF (Positive)                                         0.035 \*\*\*                          0.004
                                                        (0.010, 0.060)                        (−0.078, 0.085)
  ACPA (Positive)                                       0.008                                 0.007
                                                        (−0.015, 0.031)                       (−0.063, 0.078)
  Patient Global Assessment                             0.097 \*\*\*                          
                                                        (0.088, 0.105)                        
  Physician Global Assessment                           0.014 \*\*                            
                                                        (0.002, 0.025)                        
  ESR                                                   0.028 \*\*\*                          0.035 \*\*\*
                                                        (0.027, 0.028)                        (0.034, 0.037)
  CRP                                                   0.017 \*\*\*                          0.001
                                                        (0.015, 0.020)                        (−0.006, 0.009)
  NO${}_{2}$                                                               0.003 \*\*         0.003 \*\*\*
                                                                           (0.001, 0.005)     (0.002, 0.005)
  O${}_{3}$                                                                0.002              0.003
                                                                           (−0.002, 0.006)    (−0.001, 0.006)
  SO${}_{2}$                                                               0.004 \*\*\*       0.003 \*\*
                                                                           (0.001, 0.007)     (0.0004, 0.005)
  CO                                                                       −0.051             −0.001
                                                                           (−0.114, 0.012)    (−0.053, 0.052)
  PM${}_{10}$                                                              0.0002             0.00003
                                                                           (−0.0002, 0.001)   (−0.0003, 0.0004)
  Constant                         1.845 \*\*\*         1.029 \*\*\*       2.586 \*\*\*       1.506 \*\*\*
                                   (1.701, 1.988)       (0.966, 1.093)     (2.435, 2.738)     (1.358, 1.654)
  R${}^{2}$                        0.034                0.865              0.007              0.488
  Adjusted R${}^{2}$               0.033                0.865              0.006              0.486

Note: \*\* *p* \< 0.05; \*\*\* *p* \< 0.01.
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###### 

Coefficients estimated through HLM for CDAI (standard error in parentheses).

                                   Dependent Variable                                        
  -------------------------------- -------------------- ------------------ ----------------- ------------------
  Gender (male)                    −0.748 \*\*\*        −0.078                               
                                   (−1.187, −0.309)     (−0.218, 0.061)                      
  RA Disease Duration              −0.052 \*\*\*        0.005                                
                                   (−0.082, −0.021)     (−0.005, 0.015)                      
  Nationality (non-Kuwaitis)       1.209 \*\*\*         0.255 \*\*\*                         
                                   (0.747, 1.671)       (0.081, 0.429)                       
  Governorate (Farwaniya)          0.066                −1.199 \*\*\*                        
                                   (−1.044, 1.176)      (−1.550, −0.848)                     
  Governorate (Hawally)            3.408 \*\*\*         0.526 \*\*\*                         
                                   (2.241, 4.576)       (0.152, 0.900)                       
  Governorate (Jahra)              4.662 \*\*\*         −0.559 \*                            
                                   (3.008, 6.315)       (−1.179, 0.062)                      
  Governorate (Kuwait City)        1.947 \*\*\*         −0.135                               
                                   (0.858, 3.036)       (−0.476, 0.207)                      
  Governorate (Mubarak Alkabeer)   4.430 \*\*\*         −0.064                               
                                   (3.150, 5.709)       (−0.474, 0.345)                      
  Comorbidity (Yes)                0.984 \*\*\*         0.147 \*\*                           
                                   (0.564, 1.405)       (0.014, 0.281)                       
  Treatment Class (cDMARDs)                             −0.059                               
                                                        (−0.225, 0.107)                      
  Swollen                                               1.145 \*\*\*                         3.035 \*\*\*
                                                        (1.114, 1.175)                       (2.848, 3.222)
  Tender                                                1.423 \*\*\*                         
                                                        (1.410, 1.435)                       
  RF (Positive)                                         0.025                                −0.066
                                                        (−0.123, 0.173)                      (−0.901, 0.770)
  ACPA (Positive)                                       0.226 \*\*\*                         −0.594
                                                        (0.090, 0.363)                       (−1.320, 0.132)
  Patient Global Assessment                             1.067 \*\*\*                         
                                                        (1.059, 1.075)                       
  Physician Global Assessment                           0.871 \*\*\*                         
                                                        (0.861, 0.881)                       
  ESR                                                   0.019 \*\*\*                         0.085 \*\*\*
                                                        (0.016, 0.022)                       (0.068, 0.103)
  CRP                                                   −0.050 \*\*\*                        −0.171 \*\*\*
                                                        (−0.064, −0.037)                     (−0.246, −0.095)
  NO${}_{2}$                                                               0.040 \*\*\*      0.048 \*\*\*
                                                                           (0.022, 0.058)    (0.030, 0.066)
  O${}_{3}$                                                                0.027             0.039 \*\*
                                                                           (−0.008, 0.062)   (0.003, 0.074)
  SO${}_{2}$                                                               0.044 \*\*\*      0.044 \*\*\*
                                                                           (0.018, 0.070)    (0.018, 0.070)
  CO                                                                       −0.062            0.185
                                                                           (−0.601, 0.476)   (−0.358, 0.729)
  PM${}_{10}$                                                              0.001             0.0004
                                                                           (−0.003, 0.004)   (−0.003, 0.004)
  Constant                         4.537 \*\*\*         1.322 \*\*\*       5.306 \*\*\*      2.540 \*\*\*
                                   (3.404, 5.671)       (0.948, 1.697)     (4.006, 6.606)    (1.017, 4.064)
  R${}^{2}$                        0.030                0.925              0.015             0.299
  Adjusted R${}^{2}$               0.029                0.925              0.014             0.297

Note: \* *p* \< 0.1; \*\* *p* \< 0.05; \*\*\* *p* \< 0.01.

[^1]: Kuwait Registry for Rheumatic Diseases (KRRD) Group Members: Khulood Saleh, Adel Al-Awadhi, Adeeba Al-Herz, Waleed Al-Kandari, Eman Hasan, Aqeel Ghanem, Mohammed Hussain, Yaser Ali, Ebrahim Nahar, Ahmad Alenizi, Sawsan Hayat, Fatemah Abutiban, Ali Aldei, Hebah Alhajeri, Ali Al-Sughayer, Naser Alhadhood, Khaled Mokaddam, Ahmad Khadrawy, Youssef Bartella.
